Clinical TrialsThe gene editing program in hepatitis B virus (HBV) is advancing with a first-in-human Phase 1 trial underway, which could potentially achieve functional cure endpoints.
Financial StabilityPrecision Bio has a high cash position of approximately $121 million, providing financial stability into the second half of 2026.
Gene Editing TechnologyThe ARCUS approach is unique in a space crowded with CRISPR-based gene editing, offering distinct advantages.